查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837515

兽用抗生素和抗菌药物市场按类别、动物种类、给药途径、剂型和分销管道划分－2025-2032年全球预测

Animal Antibiotics & Antimicrobials Market by Class, Animal Species, Administration Route, Formulation, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，兽用抗生素和抗菌药物市场将成长至 10.2013 亿美元，复合年增长率为 5.45%。

关键市场统计数据
基准年2024年 6.6723亿美元
预计年份：2025年 7.0333亿美元
预测年份 2032 10.2013亿美元
复合年增长率 (%) 5.45%

简明扼要地阐述抗菌药物管理、科学进步和监管演变是塑造兽药发展的基本力量。

兽用治疗和抗菌药物管理的发展呈现出科学创新、监管审查和不断变化的商业性奖励交织而成的复杂格局。本执行摘要概述了重塑动物抗生素和抗菌药物使用格局的各种因素，重点阐述了抗菌药物管理优先事项、供应链韧性和治疗方法创新如何融合併重新定义行业实践。引言部分组装这些动态置于全球遏制抗菌素抗药性努力的背景下进行分析，同时强调了保护动物健康、福利和生产力的持续必要性。

读者将从中获得一种整合的观点，该视角将特定类别的治疗讨论与跨动物物种和给药途径的实际考虑联繫起来。透过将近期监管里程碑和贸易政策发展与製剂和诊断支援方面的技术进步并置，本部分旨在帮助相关人员了解将影响中期规划的直接营运影响和策略曲折点。其目的是在深入探讨详细的市场区隔、区域差异、企业行动和实证建议之前，为领导者提供简明扼要的概览。

诊断、管理政策和供应链数位化将如何重新定义治疗策略和市场准入

一场产业变革正在进行，科学、监管、商业和物流等多个因素相互交织，共同塑造兽用抗生素和抗菌药物的新营运标准。诊断能力的提升和对标靶治疗日益重视，正在减少对广谱经验性治疗的依赖；同时，对新型製剂和给药方法的投资，使得更精准的给药和更低的残留成为可能。同时，政策制定者和兽医监管机构正在加强监管，并推广强调合理使用、监测和可追溯性的管理框架。这些发展趋势促使生产者优先考虑那些既能证明疗效又能符合管理期望的产品系列。

在商业方面，供应链重组和数数位化正在改变产品到达终端用户的方式。可追溯系统和电子处方笺平台的兴起有助于遵守处方规定，同时製造商和经销商也在探索附加价值服务，例如诊断支援、数据分析和基本契约。此外，免疫调节剂、益生菌和精准营养等替代疗法的出现，也对传统抗生素构成了竞争压力。这些转变并非渐进式的，而是结构性的重新调整，要求企业重新思考其产品开发、打入市场策略和顾客关係模式。

评估2025年关税调整对动物保健产品价值链的采购、生产分配和商业性定位的影响。

美国2025年实施的新关税和贸易措施，增加了贸易主导的复杂性，影响了采购、生产决策和双边供应关係。关税调整影响了进口中间体和成品製剂的相对竞争力，迫使一些製造商重新评估筹资策略，检验经销商和饲料厂也必须调整其采购週期和库存管理，以降低成本波动，并维持对兽医和畜牧生产者的持续供应。

这给批发商和经销商层面的定价带来了压力，进而影响到下游流程，例如治疗方法的选择和给药途径的决策。例如，如果注射剂的物流成本增加，能够整合到水溶性或饲料基给药系统中的产品可能具有竞争优势。同时，拥有多元化配方能力和灵活生产布局的公司更有能力应对关税带来的成本变化，而不会影响服务水准。因此，关税的累积影响不仅限于直接的成本增加，还会促使整个价值链在采购、生产分配和商业性定位方面进行策略调整。

将治疗层级、物种特异性用途、给药途径、製剂和通路等因素与策略意义连结起来，进行整合细分洞察。

细分市场分析揭示了每种治疗层级、动物种类、给药途径、製剂和通路的不同驱动因素和商业性槓桿，每种情况都需要不同的策略应对措施。在考虑治疗层级时，相关人员应考虑从Aminoglycosides到四环霉素频谱（包括庆大霉素、新霉素和Aminoglycosides等亚类成分）；β-内酰胺类（包括头孢菌素和青霉素）；Fluoroquinolones（包括Ciprofloxacin、恩诺沙星和马波沙星）；大环内酯类（包括红霉素、螺旋霉素、替米考星和泰乐菌素）；磺胺类药物（包括磺胺二甲嘧啶和磺胺二甲嘧啶）；以及四环霉素（包括四环霉素、多西环素、四环霉素和四环霉素）。这些分类会影响监管风险状况、尽职调查以及配方调整的技术障碍。

从动物种类来看，水产养殖、牛、伴侣动物、家禽和猪的需求模式和用药方式差异显着，每种动物都有其独特的饲养管理方式、治疗网路基地台以及对药物残留和停药反应的敏感性。饲料添加剂和水溶液仍然是牛层面干预的重要手段，注射剂是靶向全身治疗的首选，口服和局部製剂则针对特定的临床情况，而体外给药虽然应用范围有限，但却是家禽早期疗育的重要方法。不同的製剂类型——Bolus、液体、粉末和预混合料——对生产、稳定性和剂量控制提出了不同的挑战，进而影响保存期限和易用性。饲料厂负责一体化生产系统，药房和兽医诊所提供特殊製剂，而线上管道则为伴侣饲主和小农户提供了更多便利。整合这些细分维度有助于更细緻地进行产品组合优先排序、监管规划和商业性决策，从而更好地适应每个终端使用者群体的实际运作。

在全球范围内，区域监管差异、生产体系和供应链布局如何驱动差异化的需求和打入市场策略？

区域性因素正在塑造产品需求模式、监管执法和供应策略，因此需要根据地理情况做出相应的应对。在美洲，监管现代化和对数据主导监管的重视正在推动对支持合规性和可追溯性的产品和服务的需求。欧洲、中东和非洲的监管环境复杂多样，各地的监管政策不尽相同，进口依赖性造成了一定的脆弱性，而能够实现残留物监测和低温运输完整性的技术则蕴藏着巨大的发展机会。在这个复杂的区域，许多地方既有协调统一的努力，也有各国特有的规则，因此需要灵活的註册和市场进入方式。

亚太地区的特点是兽医实践的快速现代化、水产养殖和家禽生产的持续大规模化，以及兽医用品数位化工具和电子商务的日益普及。该地区的製造能力和供应链节点在全球采购中也发挥核心作用，监管机构在调整政策以适应当地疾病压力的同时，也日益与国际标准接轨。总而言之，区域差异影响着在地化生产、通路伙伴关係以及设计符合当地基础设施和监管要求的管理支援服务的优先事项。

製造商之间的竞争行为和策略要务，揭示了研发平台、服务捆绑和製造弹性如何决定市场差异化。

公司层面的动态反映了一系列策略姿态，从垂直整合的传统企业到专业学名药生产商，再到灵活的生物技术参与企业。大型生产商正投资于平台能力建设，以加快改良产品的上市速度并加强对监管要求的合规性；而规模较小的公司和契约製造则专注于以具有成本竞争力的方式生产小众治疗层级类别或饲料级产品。诊断服务提供者与治疗药物生产商之间的策略联盟正成为一种关键模式，这种联盟能够提供结合治疗药物和决策支援工具的捆绑式解决方案，从而增强对兽医和生产者的价值提案。

此外，商业性差异化日益依赖服务产品，例如兽医教育、农场诊断和客製化给药方案，以加深客户关係并建立商品化障碍。供应链韧性和生产灵活性也正在成为核心竞争优势，尤其对于那些能够根据不断变化的客户需求和法规无缝调整製剂剂型（如Bolus、液体、粉剂和预混合料）的公司而言更是如此。最后，儘管智慧财产权和监管独占策略对于投资新型化合物和专有给药系统的公司仍然至关重要，但商业化过程通常取决于疗效、安全性和监管方面的充分验证。

采取切实可行的跨职能行动，协调研发、监管参与和商业性策略，以增强管理、供应链韧性和市场应对力。

为了因应不断变化的抗生素市场格局，行业领导者必须采取一套综合措施，协调产品开发、监管沟通和商业性执行。企业应优先投资于诊断和改进给药系统，以提高给药准确性并降低抗药性风险，同时拓展支持药物管理文件和可追溯性的能力。此外，加强供应商多元化并探索区域生产方案，有助于缓解与贸易相关的成本压力，并确保终端用户服务的连续性。

在商业层面，企业应透过教育计画、结果监测和配套服务，与兽医和饲料管理人员建立紧密的伙伴关係，凸显其产品在监管方面的高端定位。在营运层面，企业应统一不同配方产品的稳定性和持久性资料包，以加快监管互动并支持跨境註册。最后，企业领导者必须建立跨职能的管治，整合监管前瞻性、开发平臺和商业计划，确保产品组合决策既反映临床效用，也反映系统层面的监管责任。

我们透明的调查方法结合了关键相关人员的参与、监管文件审查和结构化的分析框架，以确保获得可操作和有效的见解。

本报告的调查方法结合了定性专家访谈、二手文献综述、监管文件审查以及结构化的相关人员咨询，以确保得出可靠且可操作的研究结论。主要资讯来源包括与执业兽医、生产经理、生产和分销专家以及监管负责人的讨论，以了解实践现状和新兴趋势。二手分析综合了公开的监管文件、技术专题论文和同行评审文献，以检验不同治疗类别和动物物种的临床、安全性和用药管理方面的考虑因素。

本研究采用的分析框架包括：细分映射，用于将产品属性与最终用户需求相匹配；供应链韧性评估，用于评估采购和生产的灵活性；以及情境分析，用于了解应对政策和贸易变化的潜在措施。研究对不同资料来源进行了交叉检验，以协调不同观点并对研究结果进行三角验证。在适用情况下，研究还审查了监管时间表和指导文件，以评估合规负担和註册途径。调查方法始终保持透明，以确保关键分析步骤的可重复性。

一份简洁的综合报告，重点阐述了管理协调、技术采纳和在地化供应策略将如何决定未来的竞争地位。

总之，兽用抗生素和抗菌药物市场受到日益增长的监管期望的限制，但同时也受益于技术和商业性创新，这些创新开闢了疾病预防和治疗的新途径。整合诊断工具、灵活製剂能力和符合监管要求的提案主张的相关人员将更有能力满足监管要求和客户期望。同时，区域差异和不断变化的贸易政策凸显了具有地域意识的采购和打入市场策略既能保障供应的连续性，又能满足当地的合规要求。

最终，该行业的近期发展轨迹将取决于企业如何有效地将科学进步转化为既具有临床益处又符合管理规范的产品和服务。那些迅速行动，建立跨职能合作、投资提升生产韧性并与兽医界建立务实伙伴关係关係的企业，将更有利于在日益严格的审查和快速变化的时代保持竞争力并创造差异化价值。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 在养猪业中，噬菌体疗法作为一种标靶抗菌解决方案的应用日益增多。
  • 增加对新型胜肽类抗菌药物的投资，以对抗畜牧业中的多重抗药性病原体。
  • 实施抗菌药物管理计划，以优化酪农的抗生素使用模式
  • 在农场推广快速诊断技术，以便早期发现动物感染疾病
  • 消费者对不含抗生素残留肉类的需求不断增长，推动了标籤透明度的提升。
  • 将精准兽医学与数据分析结合，以客製化抗生素给药方案
  • 开发免疫调节饲料添加剂以减少牛对传统抗生素的依赖
  • 製药公司与生技Start-Ups合作研发下一代抗生素

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按类别分類的动物抗生素和抗菌药物市场

  • Aminoglycosides
    • 庆大霉素
    • 新霉素
    • 链霉素
  • β-内酰胺类
    • 头孢菌素
    • 青霉素
  • Fluoroquinolones
    • Ciprofloxacin
    • 恩诺沙星
    • 马波沙星
  • 大环内酯类
    • 红霉素
    • 螺旋霉素
    • 替米考星
    • 泰乐菌素
  • 磺胺类药物
    • 磺胺二甲氧嗪
    • 磺胺二甲嗪
  • 四环霉素
    • 四环霉素
    • 多西环素
    • 四环霉素
    • 四环霉素

9. 依动物种类分類的动物抗生素和抗菌药物市场

  • 水产养殖
  • 牛
  • 伴侣动物
  • 家禽
  • 猪

第十章：依给药途径分類的动物抗生素和抗菌药物市场

  • 饲料添加剂
  • 蛋的内部
  • 注射
  • 口服
  • 外用
  • 水溶性

第十一章：以剂型分類的动物抗生素和抗菌剂市场

  • Bolus
  • 液体
  • 粉末
  • 预混合料

第十二章：按分销管道分類的动物抗生素和抗菌药物市场

  • 饲料厂
  • 在线的
  • 药局
  • 兽医诊所

第十三章：按地区分類的动物抗生素和抗菌剂市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 依类别分類的动物抗生素和抗菌剂市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国动物抗生素和抗菌药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • American Regent Inc.
    • Ayurvet
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Ceva Sante Animale
    • Chanelle Pharma
    • Dechra Pharmaceuticals PLC
    • Eco Animal Health Group PLC
    • Elanco Animal Health Incorporated
    • Eli Lilly and Company
    • Endovac Animal Health, LLC
    • Hester Biosciences Limited
    • Hipra Laboratories, SA
    • Inovet Group
    • Neogen Corporation
    • Norbrook Laboratories Ltd.
    • Novartis AG
    • Phibro Animal Health Corporation
Product Code: MRR-031BF22F949D

The Animal Antibiotics & Antimicrobials Market is projected to grow by USD 1,020.13 million at a CAGR of 5.45% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 667.23 million
Estimated Year [2025] USD 703.33 million
Forecast Year [2032] USD 1,020.13 million
CAGR (%) 5.45%

A concise orientation that frames antimicrobial stewardship, scientific progress, and regulatory evolution as the foundational forces shaping animal therapeutics

The evolution of veterinary therapeutics and antimicrobial management presents a dense landscape of scientific innovation, regulatory scrutiny, and shifting commercial incentives. This executive summary synthesizes the drivers reshaping animal antibiotic and antimicrobial use, focusing on how stewardship priorities, supply chain resilience, and therapeutic innovation are converging to redefine industry practice. The introduction frames these dynamics against the backdrop of global efforts to curb antimicrobial resistance, while also recognizing the enduring need to protect animal health, welfare, and productivity.

Readers will find an integrated perspective that connects class-specific therapeutic discussions with practical considerations across animal species and administration routes. By situating recent regulatory milestones and trade policy developments alongside technological advances in formulation and diagnostic support, this section primes stakeholders to understand both immediate operational impacts and the strategic inflection points that will influence medium-term planning. The intent is to equip leaders with a concise orientation before delving into detailed segmentation, regional nuance, corporate behavior, and evidence-based recommendations.

How converging advancements in diagnostics, stewardship policy, and supply chain digitalization are redefining therapeutic strategy and market engagement

Industry transformation is underway as multiple vectors-scientific, regulatory, commercial, and logistical-intersect to produce new operating norms for animal antibiotics and antimicrobials. Advances in diagnostic capability and a growing emphasis on targeted therapy are reducing reliance on broad-spectrum empiric treatments, while investments in novel formulations and delivery methods are enabling more precise dosing and reduced residues. Concurrently, policy makers and veterinary authorities are tightening oversight and promoting stewardship frameworks that emphasize judicious use, surveillance, and traceability. These developments are prompting manufacturers to prioritize product portfolios that can demonstrate both efficacy and alignment with stewardship expectations.

On the commercial front, supply chain reconfiguration and digitalization are changing how products reach end users. Enhanced traceability systems and e-prescription platforms are facilitating adherence to prescribing rules, while manufacturers and distributors explore value-added services such as diagnostic support, data analytics, and outcome-based contracts. Moreover, the emergence of alternative approaches-such as immunomodulators, probiotics, and precision nutrition-introduces competitive pressure on traditional antibiotic classes. Taken together, these shifts are not incremental; they represent a structural reorientation that requires companies to rethink product development, market access strategies, and customer engagement models.

Assessment of how 2025 tariff adjustments have reshaped sourcing, production allocation, and commercial positioning across the animal therapeutics value chain

The introduction of new tariffs and trade measures in the United States in 2025 has added an overlay of trade-driven complexity that affects procurement, manufacturing decisions, and bilateral supply relationships. Tariff adjustments have influenced the relative competitiveness of imported intermediates and finished formulations, prompting some manufacturers to reassess sourcing strategies, validate alternative suppliers, and accelerate nearshoring or regionalization of production where feasible. In parallel, distributors and feed mills have had to adapt procurement cycles and inventory management to mitigate cost volatility and maintain continuity of supply for veterinarians and livestock operations.

Consequently, pricing dynamics at the wholesale and distributor level have experienced pressure, which in turn has implications for downstream decisions about therapeutic selection and administration routes. For example, products that can be integrated into water-soluble or feed-based delivery systems may gain operational advantages when logistical costs for injectable supplies rise. At the same time, firms with diversified formulation capabilities and flexible manufacturing footprints are better positioned to absorb tariff-induced cost shifts without disrupting service levels. The cumulative impact of the tariffs therefore extends beyond immediate cost increments; it is catalyzing strategic adjustments in sourcing, manufacturing allocation, and commercial positioning across the value chain.

Integrated segmentation insights that map therapeutic classes, species-specific use, administration routes, formulations, and distribution pathways to strategic implications

Segmentation analysis reveals differentiated drivers and commercial levers across therapeutic class, animal species, administration route, formulation, and distribution channel, each demanding distinct strategic responses. When examining therapeutic class, stakeholders must account for the spectrum from aminoglycosides to tetracyclines, with subcomponents such as gentamicin, neomycin, streptomycin among the aminoglycosides and cephalosporins and penicillins within the beta-lactams; fluoroquinolones include ciprofloxacin, enrofloxacin, and marbofloxacin; macrolides encompass erythromycin, spiramycin, tilmicosin, and tylosin; sulfonamides feature sulfadimethoxine and sulfamethazine; and tetracyclines include chlortetracycline, doxycycline, oxytetracycline, and tetracycline. These class distinctions influence regulatory risk profiles, stewardship scrutiny, and technical barriers to reformulation.

Turning to animal species, demand patterns and administration norms differ markedly among aquaculture, cattle, companion animals, poultry, and swine, each exhibiting unique husbandry practices, treatment access points, and sensitivity to residue and withdrawal concerns. Administration routes shape operational use cases: feed additives and water-soluble solutions remain important for herd-level interventions, injectables are preferred for targeted systemic therapy, oral and topical forms serve specific clinical contexts, and in ovo delivery is a niche yet critical approach for early-life interventions in poultry. Formulation types such as bolus, liquid, powder, and premix present different manufacturing, stability, and dosing challenges that affect shelf life and ease of use. Distribution channels create distinct pathways to end users: feed mills serve integrated production systems, pharmacies and veterinary clinics provide professional dispensing, and online channels are expanding access and convenience for companion animal owners and smallholders. Integrating these segmentation layers enables more nuanced portfolio prioritization, regulatory planning, and commercial articulation tailored to the operational realities of each end-user segment.

How regional regulatory nuance, production systems, and supply chain footprints are driving differentiated demand and market access strategies across global regions

Regional dynamics are shaping product demand patterns, regulatory enforcement, and supply strategies in ways that require geographically informed responses. In the Americas, regulatory modernization and emphasis on data-driven stewardship are driving demand for products and services that support compliance and traceability, while strong integrated beef and poultry industries create concentrated channels for feed-based and injectable therapeutics. Europe, Middle East & Africa present a heterogeneous regulatory landscape where stewardship policies vary by jurisdiction, import dependencies create vulnerabilities, and opportunities exist for technologies that enable residue monitoring and cold-chain integrity. In many parts of this combined region, harmonization efforts coexist with country-specific rules, necessitating flexible registration and market access approaches.

Asia-Pacific is characterized by rapid modernization of veterinary practice, persistent high volumes in aquaculture and poultry production, and growing adoption of digital tools and e-commerce for veterinary supplies. The region's manufacturing capacity and supply chain nodes also play a central role in global sourcing, and regulatory authorities are increasingly aligning with international standards while adapting policies to local disease pressures. Taken together, regional contrasts influence priorities for manufacturing localization, channel partnerships, and the design of stewardship-supporting services that are sensitive to local infrastructure and regulatory expectations.

Competitive behaviors and strategic imperatives among manufacturers revealing why R&D platforms, service bundling, and manufacturing flexibility determine market differentiation

Company-level dynamics reflect a spectrum of strategic postures, ranging from vertically integrated incumbents to specialized generics producers and agile biotechnology entrants. Leading manufacturers are investing in platform capabilities that reduce time-to-market for reformulated products and enhance compliance with stewardship requirements, while smaller firms and contract manufacturers focus on niche therapeutic classes or cost-competitive production for feed-grade products. Strategic partnerships between diagnostic providers and therapeutic manufacturers are emerging as a key pattern, enabling bundled solutions that combine treatment with decision-support tools and thereby strengthen value propositions to veterinarians and producers.

In addition, commercial differentiation increasingly leverages service offerings such as veterinary education, on-farm diagnostics, and tailored dosing protocols to deepen customer relationships and create barriers to commoditization. Supply chain resilience and manufacturing flexibility are also rising as core competitive advantages, particularly for companies that can pivot between bolus, liquid, powder, and premix formats in response to customer needs or regulatory shifts. Finally, intellectual property and regulatory exclusivity strategies remain important for firms investing in novel compounds or proprietary delivery systems, though the timeline to commercialization often depends on the ability to demonstrate robust safety and stewardship-aligned efficacy.

Practical, cross-functional actions that align R&D, regulatory engagement, and commercial tactics to strengthen stewardship, supply resilience, and market responsiveness

Industry leaders must adopt an integrated set of actions that align product development, regulatory engagement, and commercial execution to navigate the evolving antimicrobial landscape. Companies should prioritize investments in diagnostic-linked therapies and reformulated delivery systems that improve dosing precision and reduce the likelihood of resistance development, while simultaneously expanding capabilities to support stewardship documentation and traceability. At the same time, strengthening supplier diversification and considering regional manufacturing options can mitigate trade-related cost pressures and maintain service continuity for end users.

On the commercial side, organizations should build closer partnerships with veterinarians and feed managers through education programs, outcome monitoring, and bundled service offerings that justify premium positioning for stewardship-compatible products. Operationally, firms should standardize stability and residue data packages across formulation types to speed regulatory interactions and support cross-border registrations. Finally, corporate leaders must foster cross-functional governance that integrates regulatory foresight, R&D pipelines, and commercial planning so that portfolio decisions reflect both clinical utility and system-level stewardship responsibilities.

A transparent methodology blending primary stakeholder engagement, regulatory dossier review, and structured analytical frameworks to ensure actionable and validated insights

The research methodology underpinning the report combines qualitative expert interviews, secondary literature synthesis, regulatory dossier review, and structured stakeholder consultations to ensure robust and actionable findings. Primary inputs include discussions with practicing veterinarians, production managers, manufacturing and distribution specialists, and regulatory affairs professionals to capture operational realities and emergent trends. Secondary analysis synthesizes publicly available regulatory documents, technical monographs, and peer-reviewed literature to validate clinical, safety, and stewardship considerations across therapeutic classes and species.

Analytical frameworks used in the study include segmentation mapping to align product attributes with end-user needs, supply chain resilience assessment to evaluate sourcing and manufacturing flexibilities, and scenario analysis to understand potential responses to policy and trade shifts. Cross-validation procedures were applied across data sources to reconcile divergent viewpoints and to triangulate findings. Where applicable, regulatory timelines and guidance documents were reviewed to assess compliance burdens and registration pathways, and methodological transparency was maintained throughout to support reproducibility of the core analytical steps.

A succinct synthesis emphasizing how stewardship alignment, technological adoption, and regionalized supply strategies jointly determine future competitive positioning

In conclusion, the animal antibiotics and antimicrobials landscape is simultaneously constrained by rising stewardship expectations and energized by technological and commercial innovations that open alternative pathways to disease prevention and treatment. Stakeholders who integrate diagnostic tools, flexible formulation capabilities, and stewardship-aligned value propositions will be better equipped to meet regulatory demands and customer expectations. Meanwhile, regional differences and trade policy developments underscore the importance of geographically aware sourcing and market entry strategies that protect supply continuity while meeting local compliance requirements.

Ultimately, the sector's near-term trajectory will be shaped by how effectively companies translate scientific advances into products and services that demonstrate both clinical benefit and stewardship compatibility. Organizations that move quickly to build cross-functional alignment, invest in manufacturing resiliency, and forge practical partnerships with the veterinary community will be best positioned to sustain relevance and create differentiated value in an era of heightened scrutiny and rapid change.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of bacteriophage therapy as targeted antimicrobial solution in swine operations
  • 5.2. Rising investment in novel peptide based antimicrobials to combat multidrug resistant pathogens in livestock
  • 5.3. Implementation of antimicrobial stewardship programs across dairy farms to optimize antibiotic usage patterns
  • 5.4. Expansion of rapid on farm diagnostic technologies for early detection of animal infectious diseases
  • 5.5. Increasing consumer demand for antibiotic residue free meat driving label transparency initiatives
  • 5.6. Integration of precision veterinary medicine using data analytics to tailor antimicrobial dosing regimens
  • 5.7. Developments in immunomodulatory feed additives to reduce reliance on traditional antibiotics in cattle
  • 5.8. Collaborations between pharmaceutical companies and biotech startups for next generation antimicrobial research

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Antibiotics & Antimicrobials Market, by Class

  • 8.1. Aminoglycosides
    • 8.1.1. Gentamicin
    • 8.1.2. Neomycin
    • 8.1.3. Streptomycin
  • 8.2. Beta Lactams
    • 8.2.1. Cephalosporins
    • 8.2.2. Penicillins
  • 8.3. Fluoroquinolones
    • 8.3.1. Ciprofloxacin
    • 8.3.2. Enrofloxacin
    • 8.3.3. Marbofloxacin
  • 8.4. Macrolides
    • 8.4.1. Erythromycin
    • 8.4.2. Spiramycin
    • 8.4.3. Tilmicosin
    • 8.4.4. Tylosin
  • 8.5. Sulfonamides
    • 8.5.1. Sulfadimethoxine
    • 8.5.2. Sulfamethazine
  • 8.6. Tetracyclines
    • 8.6.1. Chlortetracycline
    • 8.6.2. Doxycycline
    • 8.6.3. Oxytetracycline
    • 8.6.4. Tetracycline

9. Animal Antibiotics & Antimicrobials Market, by Animal Species

  • 9.1. Aquaculture
  • 9.2. Cattle
  • 9.3. Companion Animals
  • 9.4. Poultry
  • 9.5. Swine

10. Animal Antibiotics & Antimicrobials Market, by Administration Route

  • 10.1. Feed Additives
  • 10.2. In Ovo
  • 10.3. Injectable
  • 10.4. Oral
  • 10.5. Topical
  • 10.6. Water Soluble

11. Animal Antibiotics & Antimicrobials Market, by Formulation

  • 11.1. Bolus
  • 11.2. Liquid
  • 11.3. Powder
  • 11.4. Premix

12. Animal Antibiotics & Antimicrobials Market, by Distribution Channel

  • 12.1. Feed Mills
  • 12.2. Online
  • 12.3. Pharmacies
  • 12.4. Veterinary Clinics

13. Animal Antibiotics & Antimicrobials Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Animal Antibiotics & Antimicrobials Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Animal Antibiotics & Antimicrobials Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. American Regent Inc.
    • 16.3.2. Ayurvet
    • 16.3.3. Bayer AG
    • 16.3.4. Boehringer Ingelheim GmbH
    • 16.3.5. Ceva Sante Animale
    • 16.3.6. Chanelle Pharma
    • 16.3.7. Dechra Pharmaceuticals PLC
    • 16.3.8. Eco Animal Health Group PLC
    • 16.3.9. Elanco Animal Health Incorporated
    • 16.3.10. Eli Lilly and Company
    • 16.3.11. Endovac Animal Health, LLC
    • 16.3.12. Hester Biosciences Limited
    • 16.3.13. Hipra Laboratories, S.A.
    • 16.3.14. Inovet Group
    • 16.3.15. Neogen Corporation
    • 16.3.16. Norbrook Laboratories Ltd.
    • 16.3.17. Novartis AG
    • 16.3.18. Phibro Animal Health Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ANIM